| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | NU58DP007131 | Cancer Prevention and Control Program 3: National Program of Cancer Registries | 01 | 4 | CDC | 11/10/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | NU58DP007131 | Cancer Prevention and Control Program 3: National Program of Cancer Registries | 01 | 4 | CDC | 11/10/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | T9952113 | Value-Based Medical Student Education Training Program | 01 | 3 | HRSA | 11/4/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | NUR3DD000102 | The Utah Registry of Autism and Developmental Disabilities: Enhancing Public Health Surveillance of Autism Spectrum Disorder in Utah through the Autism and Developmental Disabilities Monitoring (ADDM) | 01 | 3 | CDC | 11/10/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | NU58DP007131 | Cancer Prevention and Control Program 3: National Program of Cancer Registries | 01 | 4 | CDC | 11/10/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | NU58DP007131 | Cancer Prevention and Control Program 3: National Program of Cancer Registries | 01 | 4 | CDC | 11/10/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | NU58DP007131 | Cancer Prevention and Control Program 3: National Program of Cancer Registries | 01 | 4 | CDC | 11/10/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | NU58DP007131 | Cancer Prevention and Control Program 3: National Program of Cancer Registries | 01 | 4 | CDC | 11/10/2025 | $0 |
| | 2026 | 2024 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | NUR3DD000102 | The Utah Registry of Autism and Developmental Disabilities: Enhancing Public Health Surveillance of Autism Spectrum Disorder in Utah through the Autism and Developmental Disabilities Monitoring (ADDM) | 01 | 3 | CDC | 11/10/2025 | $0 |
| | 2026 | 2023 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | NUR3DD000102 | The Utah Registry of Autism and Developmental Disabilities: Enhancing Public Health Surveillance of Autism Spectrum Disorder in Utah through the Autism and Developmental Disabilities Monitoring (ADDM) | 01 | 3 | CDC | 11/10/2025 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $289,013,128 ) (Continued on the next page) |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | F31DK141216 | Investigation of the dynamics and mechanisms of colitis-induced neuroinflammation | 000 | 1 | NIH | 6/25/2025 | $40,318 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R33AT012329 | Specialized pro-resolving lipid mediators and treatment resistant depression | 001 | 3 | NIH | 4/1/2025 | $134,417 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R33AT012329 | Specialized pro-resolving lipid mediators and treatment resistant depression | 001 | 3 | NIH | 4/1/2025 | $344,663 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R21AI188073 | A 3-In-One Design of CAR Tregs for Robust Immunotolerance | 000 | 1 | NIH | 6/26/2025 | $423,500 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01CA249185 | Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implications | 004 | 6 | NIH | 7/11/2025 | $352,270 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R21DC022648 | Neural basis of precedence-type sound localization processes | 000 | 1 | NIH | 3/20/2025 | $189,530 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01DC021938 | Biomechanical Mechanisms of Benign Paroxysmal Positional Vertigo | 000 | 1 | NIH | 3/19/2025 | $514,546 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R33AT012329 | Specialized pro-resolving lipid mediators and treatment resistant depression | 001 | 3 | NIH | 4/1/2025 | $40,284 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | K23HL175226 | Role of Angiotensin II in Cardiogenic Shock Pathophysiology and Outcomes | 000 | 1 | NIH | 7/17/2025 | $189,000 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | K23HD115855 | Anakinra Dosing in Children with Sepsis Induced MODS: A Physiologically Based Pharmacokinetic-Pharmacodynamic Approach | 000 | 1 | NIH | 9/5/2025 | $167,400 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | UG1HD119614 | University of Utah: The Road to Prevention of Stillbirth Clinical Research Center | 000 | 1 | NIH | 8/29/2025 | $1,302,264 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01AG096179 | Examining Effects of Intensive BP Control on MCI/Dementia and Plasma Biomarker Trajectories by AD Pathology: Elucidating neuroprotective effects in the racially and ethnically diverse SPRINT trial | 000 | 1 | NIH | 9/15/2025 | $5,789,766 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R21NR021748 | A real-time surveillance system for detecting local spikes of food insecurity to inform timely interventions | 000 | 1 | NIH | 9/12/2025 | $423,500 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R33HL169189 | A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation | 000 | 3 | NIH | 9/20/2025 | $544,885 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | F31HL180033 | Role of cell-specific durotaxis in pulmonary arterial hypertension pathogenesis | 000 | 1 | NIH | 9/20/2025 | $41,807 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | UH3AT012859 | Holistic Pain Care in Military Health System | 000 | 2 | NIH | 9/5/2025 | $1,159,049 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | UH3AT012859 | Holistic Pain Care in Military Health System | 000 | 2 | NIH | 9/5/2025 | $100,000 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | K22CA289144 | Determining immune-mediated mechanisms of beneficial bacteria in colon cancer | 000 | 1 | NIH | 9/10/2025 | $201,960 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01DK141142 | Mechanisms of mitochondria-driven hepatocyte injury | 000 | 1 | NIH | 8/26/2025 | $729,085 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | F31DK141265 | Clec12A regulation of the intestinal immune response and microbiota composition | 001 | 1 | NIH | 9/10/2025 | $0 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | F31DK141265 | Clec12A regulation of the intestinal immune response and microbiota composition | 000 | 1 | NIH | 9/10/2025 | $42,418 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01HL181498 | Integrating multi-omics data to understand the heterogeneity of preeclampsia and long-termpostpartum hypertension | 000 | 1 | NIH | 9/5/2025 | $524,179 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01AG083580 | Geriatric assessment domains in relation to treatment outcomes among older adults with colorectal cancer | 001 | 2 | NIH | 6/10/2025 | $61,985 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01AG083580 | Geriatric assessment domains in relation to treatment outcomes among older adults with colorectal cancer | 000 | 2 | NIH | 3/20/2025 | $697,349 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R34AT013448 | Waning Moon: A Whole Person Health Intervention Designed by and for Urban Menopausal American Indian/Alaska Native Women | 000 | 1 | NIH | 8/26/2025 | $50,000 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R34AT013448 | Waning Moon: A Whole Person Health Intervention Designed by and for Urban Menopausal American Indian/Alaska Native Women | 000 | 1 | NIH | 8/26/2025 | $100,000 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R34AT013448 | Waning Moon: A Whole Person Health Intervention Designed by and for Urban Menopausal American Indian/Alaska Native Women | 000 | 1 | NIH | 8/26/2025 | $42,500 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01NS140319 | Overcoming Therapy Resistance in Hedgehog Pathway-Driven Medulloblastoma | 000 | 1 | NIH | 7/31/2025 | $611,591 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | F31HL182256 | Deciphering the output of fetal hematopoietic stem and progenitor cells at homeostasis and in response to inflammation | 000 | 1 | NIH | 8/29/2025 | $38,804 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | U01NS120901 | A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease | 003 | 4 | NIH | 9/17/2025 | $50,489 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | U01NS120901 | A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease | 002 | 3 | NIH | 9/16/2025 | -$50,489 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | U01NS120901 | A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease | 001 | 4 | NIH | 8/18/2025 | $3,478,888 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | U01NS120901 | A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease | 000 | 3 | NIH | 7/15/2025 | $50,489 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01CA176839 | Targeting Oncogenic NRAS, BRAF plus PI3'-Kinase Signaling for Melanoma Therapy | 001 | 8 | NIH | 6/3/2025 | $38,500 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01CA176839 | Targeting Oncogenic NRAS, BRAF plus PI3'-Kinase Signaling for Melanoma Therapy | 000 | 8 | NIH | 3/7/2025 | $346,500 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | R01HL165119 | The Pathophysiology of Type 1 Versus Type 2 Mutant Calreticulin-Drivenmyeloproliferative Neoplasms | 002 | 4 | NIH | 8/14/2025 | $463,672 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | T35DK103596 | MSRP in Metabolism, Diabetes, Digestive and Kidney Diseases | 001 | 10 | NIH | 8/20/2025 | $28,242 |
| | 2025 | 2025 | UNIVERSITY OF UTAH | 201 PRESIDENTS CIR | SALT LAKE CITY | UT | 84112-9049 | SALT LAKE | USA | T35DK103596 | MSRP in Metabolism, Diabetes, Digestive and Kidney Diseases | 000 | 10 | NIH | 3/3/2025 | $44,200 |
|
